| Name | Tirabrutinib hydrochloride |
| Description | Tirabrutinib hydrochloride is a potent, highly selective, and irreversible oral BTK inhibitor. Tirabrutinib hydrochloride irreversibly covalently binds to Bruton tyrosine kinase (BTK) in B cells and exhibits potent in vitro cytotoxicity against many types of B cell malignancies, as well as in vivo antitumor activity in mouse models [1]. |
| In vitro | METHODS: Tirabrutinib hydrochloride (0.1-1000 nM or 0.001-100 nM; 72 h) was used to treat DLBCL cell lines SU-DHL-6 and OCI-LY10 to observe the anti-tumor effect on cells.
RESULTS The IC50 values of Tirabrutinib hydrochloride against SU-DHL-6 and OCI-LY10 cell lines were 9.127 μM, and 17.10 μM.[1] |
| In vivo | Parental TMD8 mice were treated with tirabrutinib (6, 20 mg/kg; p.o.) to confirm whether tirabrutinib remains active in vivo.
RESULTS 0.012% of tirabrutinib resulted in tumor remission in mice. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 95 mg/mL (193.51 mM), Sonication is recommended.
|
| Keywords | B cells | ONO 4059 | haematological malignancies | Bruton tyrosine kinase | PCNSL | Tirabrutinib | GS-4059 | Inhibitor | ONO-4059 | Tirabrutinib Hydrochloride | ONO4059 | GS4059 | autoimmune disorders | Tirabrutinib hydrochloride | Apoptosis | Btk | inhibit | GS 4059 |
| Inhibitors Related | evobrutinib | (±)-Zanubrutinib | CP-547632 | BMS-986142 | Edralbrutinib | Sunvozertinib | Ibrutinib | IBT6A | Orelabrutinib | Atuzabrutinib | Remibrutinib | CGI-1746 |
| Related Compound Libraries | Highly Selective Inhibitor Library | Bioactive Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
